Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target

Olga A. Sukocheva, Hideki Furuya, Mei Li Ng, Markus Friedemann, Mario Menschikowski, Vadim V. Tarasov, Vladimir N. Chubarev, Sergey G. Klochkov, Margarita E. Neganova, Arduino A. Mangoni, Gjumrakch Aliev, Anupam Bishayee

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Inflammatory gastrointestinal (GI) diseases and malignancies are associated with growing morbidity and cancer-related mortality worldwide. GI tumor and inflammatory cells contain activated sphingolipid-metabolizing enzymes, including sphingosine kinase 1 (SphK1) and SphK2, that generate sphingosine-1-phosphate (S1P), a highly bioactive compound. Many inflammatory responses, including lymphocyte trafficking, are directed by circulatory S1P, present in high concentrations in both the plasma and the lymph of cancer patients. High fat and sugar diet, disbalanced intestinal flora, and obesity have recently been linked to activation of inflammation and SphK/S1P/S1P receptor (S1PR) signaling in various GI pathologies, including cancer. SphK1 overexpression and activation facilitate and enhance the development and progression of esophageal, gastric, and colon cancers. SphK/S1P axis, a mediator of inflammation in the tumor microenvironment, has recently been defined as a target for the treatment of GI disease states, including inflammatory bowel disease and colitis. Several SphK1 inhibitors and S1PR antagonists have been developed as novel anti-inflammatory and anticancer agents. In this review, we analyze the mechanisms of SphK/S1P signaling in GI tissues and critically appraise recent studies on the role of SphK/S1P/S1PR in inflammatory GI disorders and cancers. The potential role of SphK/S1PR inhibitors in the prevention and treatment of inflammation-mediated GI diseases, including GI cancer, is also evaluated.

Original languageEnglish
Article number107464
JournalPharmacology and Therapeutics
Volume207
Early online date18 Dec 2019
DOIs
Publication statusPublished - Mar 2020

Keywords

  • Colitis
  • Colon cancer
  • Esophageal cancer
  • Fingolimod
  • Gastric cancer
  • Inflammatory bowel disease
  • Microbiome
  • Sphingosine kinase
  • Sphingosine-1-phosphate
  • Sphingosine-1-phosphate receptor

Fingerprint Dive into the research topics of 'Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target'. Together they form a unique fingerprint.

  • Cite this

    Sukocheva, O. A., Furuya, H., Ng, M. L., Friedemann, M., Menschikowski, M., Tarasov, V. V., Chubarev, V. N., Klochkov, S. G., Neganova, M. E., Mangoni, A. A., Aliev, G., & Bishayee, A. (2020). Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: A novel therapeutic target. Pharmacology and Therapeutics, 207, [107464]. https://doi.org/10.1016/j.pharmthera.2019.107464